PSS14 A PATIENT SURVEY/CHART REVIEW STUDY ABOUT TREATMENT PATTERNS, COSTS AND QUALITY OF LIFE IN PATIENTS WITH PSORIASIS IN SWEDEN  by Hjortsberg, C et al.
A454 Paris Abstracts
model was developed to perform a cost analysis of OSCHE in patients refractory to 
topical corticosteroids from an employer’s mutual insurance company perspective over 
a one year time horizon. A structured questionnaire was elaborated and answered by 
a Spanish panel of four dermatologists and two occupational physicians, to identify 
therapeutic management and estimate the use of resources associated to OSCHE. The 
clinical information was obtained from published literature and was complemented 
by physicians. The information regarding costs associated to the different types of 
disability was obtained from data of 156 patients from one of the main EMIC in 
Spain. Disabilities are classiﬁed by EMIC in three groups according to the time spent 
on sick leave: Partial disability (3 months), partial permanent disability (24 months) 
and total permanent disability (limited to current profession). RESULTS: Annual total 
costs of OSCHE for a Spanish EMIC were on average over a60,000 per patient. Direct 
costs represented 1.4% and indirect costs 98.6% of total costs. Total permanent dis-
ability was the most important cost driver, representing 69.3% of total costs, although 
only 18% of patients were estimated to reach this type of disability. CONCLUSIONS: 
Disability is the most important predictor of total costs in patients with OSCHE for 
the EMIC in Spain. Indirect costs are by far the most important cost driver (98.6%) 
for this disease. An effective therapy for OSCHE may signiﬁcantly reduce the number 
of disabilities and therefore indirect costs.
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OBJECTIVES: To estimate the total costs of moderate to severe psoriasis patients in 
Spain. METHODS: An observational study was conducted at 123 centers in Spain 
recruiting 1217 patients (60.8% males, mean age 45.1 o 13.9 years, 95.6% with active 
treatment) with moderate (60.8%) to severe (39.2%) psoriasis (VACAP study). Direct 
and indirect resource consumption during the study was collected for every patient 
using patient notebooks. Direct resource use consisted in inpatient hospitalization, 
surgeries, emergency room visits, consultations (primary and secondary care, nursery, 
other health care professionals and alternative medicine visits), laboratory and diag-
nostic tests, medication (prescription and non-prescription drugs paid by patients), 
and phototherapy sessions. Indirect costs included productivity losses (full or part-
time), social assistance and out-of-pocket expenses paid directly by patients (travel 
costs, formal caregivers). Resource use unitary costs were obtained from e-Salud 
database. Four-month costs were extrapolated to annual costs (a, year 2009 values). 
RESULTS: Mean annual total cost per patient was a6881 (95% conﬁdence interval 
[CI], a5365–a8370). Direct and indirect costs accounted for a6420 (95%CI, a5067–
a7745) and a461 (95%CI, a299–a625) representing 93.3% and 6.7% of total esti-
mated costs respectively. The most important categories of direct costs were 
prescription medication (a3667, 95%CI, a2954–a4381, 53.3% of direct costs), pho-
totherapy sessions (a1405, 95%CI, a1144–a1666, 20.4%), consultations (a517, 
95%CI, a434–a567, 7.5%) and hospital day visits (a436, 95%CI, a294–a578, 6.3%) 
The most signiﬁcant indirect costs were loss of productivity (a357, 95%CI, a216–
a500, 77.5% of indirect costs) and travel costs (a85, 95%CI, a76–a95, 18.5%). 
CONCLUSIONS: In Spain, mean annual cost per patient with moderate to severe 
psoriasis represents a6881, of which 93% were direct costs and 7% indirect costs.
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OBJECTIVES: This study estimated the economic consequences of topical moxiﬂoxa-
cin compared with topical oﬂoxacin in the treatment of acute infectious conjunctivitis 
in Scotland (SC), Spain (ES) and The Netherlands(NL). METHODS: The rates of 
treatment failure, deﬁned as no improvement or worsening symptoms, were estimated 
by a meta-analysis of randomized controlled trials (RCT) of moxiﬂoxacin. The 
resources consumed and costs of treatment failure were assessed by a survey of 39 
General Practitioners (GP) and 14 Ophthalmologists (OPH). National databases were 
used to estimate resource costs. The potential economic beneﬁt was estimated, and 
sensitivity analyses were performed using moxiﬂoxacin’s failure rate advantage from 
trials directly comparing the drugs and meta-analysis of patients with conﬁrmed bacte-
rial infection (from 3.3% to 6.5% lower). RESULTS: Treatment failure costs are 
driven by extra physician consultations,and bacterial cultures. The average cost of a 
treatment failure in ES, SC and NL respectively is a38, a72, a53 when managed by a 
GP compared to OPH estimates of a108, a133, and a215. OPH extremes were a93 
to a279a. Assuming 1.5% of the population experiences acute infectious conjunctivitis 
and a 10% failure rate in symptomatic improvement in control group patients, the 
estimated annual cost of failure ranges from a57,000a to a322,500 per million inhabit-
ants. Primarily OPH use the studied drugs. With 4.7% less treatment failure when 
moxiﬂoxacin instead of oﬂoxacin is used by OPH, the economic beneﬁt was estimated 
at a5.1, a6.3, a10.13 per patient in ES, SC and NL respectively. This is a cost saving 
of approximately 11% on specialist treatment independent of the country. Sensitivity 
analysis resulted in an economic beneﬁt from a3.58 to a14.01 as extremes of all 
countries. CONCLUSIONS: The decrease of treatment failure rate using moxiﬂoxacin 
instead of oﬂoxacin in acute infectious conjunctivitis provides an economic beneﬁt in 
three countries of interest.
PSS12
THE ECONOMIC IMPACTS OF ACUTE OTITIS MEDIA IN TAIWAN
Wang PC1, Chang CJ2, Chang CH1, Chuang LJ1
1Cathay General Hospital, Taipei, Taiwan, 2Chang Gung University, Taoyuan, Taiwan
OBJECTIVES: Acute otitis media (AOM) is the most common childhood infection 
next to common cold. The impacts of AOM deserve attentions from both public health 
and economic perspectives. Taiwan’s National Healthcare Insurance (NHI) provides 
comprehensive coverage and to date, over 97% of the populations are insured. In this 
study we use the NHI claim database to evaluate the economic impacts of AOM. 
METHODS: We reviewed the claims of pediatric patients with AOM who had 
received treatment during January 1–December 31, 2006. Numbers of visits and 
expenses (in $New Taiwan Dollars, exchange rate with $USD 32^33.5 during year 
2006) were calculated. The data size is around 400 gigabytes. RESULTS: The mean 
age of disease was 5.4 years-old. With 29.6 % under 3 years-old, 48.1% under 7 
years, and 22.3 % under 12 years-old. The male: female ratio was: 1.2:1. There were 
733,546 visits related to the occurrence of AOM, 717,263 (visits) occurred in outpa-
tient settings; 16,283 admissions were related to AOM care. A total of 45.8% 
(328,517 out of 717,263 visits) were treated by pediatricians, 35.2% (252,347 visits) 
were treated by otolaryngologists, and 4.6% (34,840 visits) were treated by family 
practitioners. Around 97.0% (15,799 out of 16,283 admissions) were under pediatric 
and 1.7% (281) were under otolaryngology services. The total annual expenses related 
to AOM care was 554,507,868 $NTD, comprising of 315,671,421 $NTD in outpa-
tient (56.9%), and 238,836,447 $NTD in inpatient cares (43.1%). In average, AOM 
took 3.6 antibiotics-days, and 4.5 admission-days to treat. CONCLUSIONS: Over 
half of the AOM care expenses were spent in ambulatory services. Pediatricians took 
46% outpatient and 97% inpatient AOM care resources. The nation-wide economic 
impact of AOM was around 0.55 billion $NTD annually. The NHI claim database 
provides possibility for further economic analysis.
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OBJECTIVES: To compare the cost of cataract surgery in patients with and without 
astigmatism, as reported in the French national Diagnosis Related Group (DRG) 
database (PMSI: Programme de Médicalisation des Systèmes d’Information). 
METHODS: The 2007 DRG database was used. Patients with cataract surgery were 
identiﬁed by the surgery procedure codes (BFGA001-BFGA010; BFLA001-BFLA004). 
Patients with declared astigmatism had a H522 ICD10 code. DRG standard cost was 
adjusted according to the number of procedures. Surgery and anaesthesia costs esti-
mated from the Echelle National des Coûts were adjusted with the same method. 
Average costs were calculated in both groups. Student t-test and chi-square were used 
to compare the two groups. RESULTS: A total of 475 declared astigmatic and 579,778 
without declared astigmatism patients were extracted (age: 73.6 years, 2 males: 3 
females). Astigmatic patients were more often operated on in a private hospital. 
Astigmatic patients showed a trend towards a longer length of stay (2.41 versus 2.17 
days; p  0.12, ambulatory patients excluded), more co-morbidity (2.38 versus 1.03; 
P  0.001) and more procedures (3.03 versus 2.43; P  0.001). The cost of procedures 
was higher for astigmatic patient (a580 versus a464) leading to a higher total hospital 
cost (a1488 versus a1372). CONCLUSIONS: Astigmatism is dramatically under-
reported in the PMSI database in comparison to nationwide prevalence rate estimates. 
Astigmatic patients required more procedures, partially due to increased co-morbidity. 
An astigmatic patient costs more and this is not taken into account by today’s V11 
clustering cost algorithm. Time and motion analysis should be conducted to better 
understand astigmatism management during cataract surgery.
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OBJECTIVES: Psoriasis is a chronic disease with signiﬁcant psychosocial morbidity 
and lower health-related quality of life (QoL). In Sweden, an estimated 250,000 
persons or nearly 3% of the population have psoriasis. There are few studies on the 
total cost of psoriasis therapy, especially studies that take both direct and indirect 
costs into account. The aim of the present study was to analyse and estimate health 
related QoL and costs of psoriasis during a year in relation to disease severity among 
psoriasis patients, based on patient populations from two dermatology centres in 
Sweden. METHODS: The study is based on data from three sources; a patient survey, 
a retrospective chart review, and data from a drug registry. Information about Qol 
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(EQ-5D), disease severity (DLQI), resource utilisation and productivity losses was 
collected from patient questionnaires. Patient characteristics and type of treatment 
were collected from patient records. Prescribed medications were collected from 
national drug registry data. RESULTS: During 12 months, 64% of the patients used 
only emollients and topical corticosteroids and 21% used systemic treatment (not 
biological). During part of or during the whole period 15% used biological treatment. 
Mean direct cost per patient related to in and out-patient care was estimated to a488, 
and indirect cost was a758. Cost for drugs was a1892 per patient and cost for light 
treatment was a930. QoL according to EQ-5D was 0.73 (SD 0.25), VAS 72.7 (SD 
20.6) and DLQI was 7.0 (SD 6.6) corresponding to “moderate effect on patient’s life”. 
CONCLUSIONS: Patients with more extensive psoriasis problems experienced lower 
QoL according to EQ-5D and higher discomfort and a larger effect on their lives 
according to DLQI. Direct and indirect costs increased with disease severity. Costs 
increased with the use of more potent drugs (biological and systemic drugs).
PSS15
COSTS OF GLAUCOMA IN DENMARK
Olsen J1, Berdeaux G2
1University of Southern Denmark, Odense, Denmark, 2Conservatoire National des Arts et 
Métiers, Paris, Hauts de Seine, France
OBJECTIVES: To describe costs of glaucoma treatment in Denmark by treatment 
sequence. METHODS: The analyses were based on registry data. A new or incident 
patient was deﬁned as a patient who did not use any medicine related to glaucoma 
for 6 months—that is, the study estimated the number of new patients in a 5.5 year 
period (from mid-2002 to 2007). New (incident) glaucoma patients (primary open-
angle glaucoma or ocular hypertension) were deﬁned via their “ﬁrst” use of prescribed 
medicine related to glaucoma (that is, via the ATC-codes) and the patients were identi-
ﬁed in the Danish Register of Medicinal Product Statistics for the years 2002–2007. 
Subsequently a cross sectional analysis for 2007 was performed including use of 
medicine related to glaucoma and use of services in the primary (ophthalmologists’ 
services) and secondary care services (relevant out-patient treatment and admissions 
—relevance deﬁned by a ICD10 code). Patients were categorized according to their 
number of treatment changes. RESULTS: Based on these data the yearly Danish inci-
dence was estimated to 1.2 per 1000 persons. The sex ratio (male/female) was 
44%/56% with a mean age of 68 and 71 years, respectively. Thirty-seven percent of 
the patients were in their ﬁrst treatment sequence (that is, no treatment changes), 21 
% were in their second, and 43 % of the patients had 3 or more treatment sequences. 
The number of treatment sequences inﬂuenced cost. The total costs of glaucoma 
(public payer perspective) were DKK 2200 (a300) per year for a patient in ﬁrst treat-
ment sequence whereas the corresponding costs for a patient with 3 or more treatment 
sequences were DKK 4600 (a610). Drug cost accounted for 62% of the total. CON-
CLUSIONS: Drugs represent the bulk of the costs of glaucoma and the costs increases 
with the number of treatment changes.
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OBJECTIVES: Use decision making tools to determine which of three alternatives—
Cochlear Implants, Hearing aids or no treatment- assure that a person, who suffers 
from Deep Neursosensorial Hypoacusia, will achieve the best cost-productivity rela-
tion for his or her life. METHODS: This study is based on a decision making analysis 
methodology which includes a description of the problem, a bibliographic review, a 
formulation of the problem, data analysis and incorporation, a mathematical model 
and results analysis. The problem is described as an alternatives issue concerning dif-
ferent treatments for Deep Neurosensorial Hypoacusia and a cost-productivity rela-
tion in order to evaluate each of the alternatives. This relation is measured as the NPV 
of the salary cash ﬂow that the patient expects to receive during his/her productive 
life as compared with the treatment and education costs. Actual data from the 
Cochlear Group of the Fundacion Santafe concerning audiology and language com-
prehension levels from patients using different treatments for deep deafness is analyzed 
in order to generate probability distributions and develop an inﬂuence diagram. 
Finally, a sensitivity analysis is conducted in order to verify the robustness of the 
solution obtained. RESULTS: As a result of the study was obtained that the cochlear 
implant provides a cost-productivity relation of COP$253,936,210 (US$123,871), 
Hearing aids: COP$ 138,307,940 (US$67,467) and not following any treatment: 
COP$107,510,318 (US$52,444). According to this assessment, the cochlear implant 
is the best treatment. CONCLUSIONS: According to the results, individuals who use 
a cochlear implant have a productivity of 1.5 times higher for individuals with hearing 
aids and almost 3 times higher than individuals who do not follow any treatment. 
This conﬁrms the excellent performance in terms of effectiveness and utility of the 
cochlear implant compared to hearing aids. The sensitivity analysis conducted showed 
that the cochlear implant is the best decision in a real scenario.
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OBJECTIVES: Non-compliance is frequently reported as a cause of treatment failure 
of oral antimicrobials. As the long-term injectable cefovecin eliminates non-compliance, 
the study objective was to investigate the impact of non-compliance on the costs and 
effectiveness of treatment of superﬁcial pyoderma, wounds and abscesses (SP-W-A), 
and deep pyoderma (DP) in dogs in Germany. METHODS: A Markov model, contain-
ing the health states “Worsening”, “Status quo”, “Improvement”, “Cure”, and 
“Relapse”, was adapted to Germany to calculate costs and beneﬁts (days without 
symptoms of SP-W-A or DP) over a 6-months (SP-WA) and 1-year (DP) period, for 
dogs on cefovecin versus amoxicillin/clavulanic acid (amoxi/clav). Efﬁcacy parameters 
were derived from clinical studies. For amoxi/clav, ﬁrst line treatment failure caused 
by non-compliance was estimated at 13.6% of all dogs, calculated from published 
literature. Cost data were derived from German ofﬁcial price and tariff lists (2009, 
dog owner’s perspective). All relevant input parameters were varied extensively in 
one-way and probabilistic sensitivity analyses. RESULTS: Cefovecin was more effec-
tive than amoxi/clav, with 161 versus 156 days without symptoms of SP-W-A and 
316 versus 307 days without symptoms of DP. Up to a bodyweight (b.w.) of 15 kg 
(SP-W-A) or 16 kg (DP), cefovecin was a dominant strategy, i.e. also cost-saving when 
considering total therapy expenditure (including anamnesis, diagnosis, treatment). In 
dogs of 25 kg b.w., total therapy costs for cefovecin were slightly increased versus 
comparator, a297.25 versus a272.72 (SP-W-A) and a 498.60 versus a477.75 (DP). 
Model outcomes were sensitive to changes of non-compliance data, but remained 
robust when varying other parameters. CONCLUSIONS: Considering non-compli-
ance with oral treatments as a cause of treatment failure, higher drug and administra-
tion costs of cefovecin became totally or partly offset by the increased incremental 
efﬁcacy resulting in less costs for supplementary treatments of relapses and failures.
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OBJECTIVES: Topical prostaglandin analogs combined with timolol demonstrate 
strong intra-ocular pressure lowering effect and are indicated in second line treatment. 
This study aims to estimate the 5-years cost effectiveness of Duotrav® and Xalacom® 
in second line glaucoma treatment in France from the perspective of the health care 
system. METHODS: A 5 year Markov model was built to populate the treatment of 
two cohorts of glaucoma patients. Time to treatment modiﬁcation, a key cost factor 
in real life, was estimated on the basis of an analysis of the UK GPRD database and 
a hazard-ratio (DuoTrav vs Xalacom) taken from a French observational study. Visual 
ﬁeld defect (VFD) occurrence rathes by treatment line were estimated from the litera-
ture. French standard costs were applied. Sensitivity analyses were carried out. 
RESULTS: Average times to treatment changes were 38.0 and 31.1 months for 
Duotrav and Xalacom, respectively. A total of 45.4% of the patients remained with 
their treatment at 5 years in the Duotrav cohort compared with 29.1% in the Xalacom 
group. The clinical beneﬁt of Duotrav was 0.06 less new VFDs on average per patient. 
The longer duration of treatment with Duotrav was associated with an extra costs of 
a144, an amount that was totally offset by a decrease in operating procedures (a98.7) 
and cost of rescue medications (a98.5). Other resources used (visits, exams..) were 
similar. Total costs were lower in the Duotrav cohort (a81.8) than in the Xalacom 
cohort. Sensitivity analyses conﬁrmed these ﬁndings. CONCLUSIONS: Treatment 
persistency is a key indicator of the effectiveness of chronic disease treatment in daily 
practice. The longer duration of treatment with Duotrav as compared with Xalacom 
lead to better glaucoma control, less VFD progression, and lower medical care costs. 
According to this analysis, DuoTrav economically dominates Xalacom.
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OBJECTIVES: Cefovecin, an injectable antimicrobial, maintains a therapeutic tissue 
concentration for approximately 14 days, and hence eliminates non-compliance 
reported with oral comparators. This study compared treatment costs and effectiveness 
of oral medication to cefovecin in resolving superﬁcial pyoderma, wounds, and 
abscesses (SP-W-A) in dogs. METHODS: A Markov model was developed to reﬂect 
treatment with cefovecin versus oral amoxicillin/clavulanic acid (amoxi/clav) over a 
six months period. The health states “Worsening”, “Status quo”, “Improvement”, 
“Cure”, and “Relapse” were included to reﬂect treatment costs and outcomes of ﬁrst, 
second and third line therapy protocols and account for treatment relapses. Effective-
ness parameters were derived from published clinical studies. For amoxi/clav, ﬁrst 
line treatment failure caused by non-compliance was estimated at 13.6% of all dogs 
